{"preliminary_commentary":{"by_channel":{"x_thread":14,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03768414\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nab-paclitaxel"]],"indication":"newly diagnosed advanced biliary tract cancers","name":"SWOG S1815","nct_id":"NCT03768414","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-s1815-nct03768414. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)","type":"EXPERIMENTAL"},{"description":"Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (cisplatin, gemcitabine hydrochloride)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2024-10-28","type":"ACTUAL"},"conditions":["Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Distal Bile Duct Cancer AJCC v8","Stage IIIA Gallbladder Cancer AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Distal Bile Duct Cancer AJCC v8","Stage IIIB Gallbladder Cancer AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Stage IVA Gallbladder Cancer AJCC v8","Stage IVB Gallbladder Cancer AJCC v8","Unresectable Extrahepatic Bile Duct Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Gemcitabine Hydrochloride","otherNames":["dFdCyd","Difluorodeoxycytidine Hydrochloride","Gemzar","LY-188011","LY188011"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["ABI 007","ABI-007","Abraxane","Albumin-bound Paclitaxel","Albumin-Stabilized Nanoparticle Paclitaxel","Nanoparticle Albumin-bound Paclitaxel","Nanoparticle Paclitaxel","paclitaxel albumin-stabilized nanoparticle formulation","Protein-bound Paclitaxel"],"type":"DRUG"}],"last_update":"2026-01-12","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-10-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 3 years"}],"references":[{"citation":"Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley RK, Thumar J, El-Khoueiry A, Guthrie KA, Chiorean EG, Hochster H, Philip PA. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10;43(5):536-544. doi: 10.1200/JCO-24-01383. Epub 2024 Dec 13.","pmid":"39671534","type":"DERIVED"}],"start_date":{"date":"2019-02-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers","url":"https://clinicaltrials.gov/study/NCT03768414"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-s1815-nct03768414"}